Sarpogrelate

• MCI - 9042
• LS- 187 118
• 4 - [2 - (dimethylamino ) -1 - ( {2 - [ 2 - (3 -methoxyphenyl) ethyl] phenoxy} methyl) ethoxy] -4- oxobutanoic acid (IUPAC)

Antiplatelet

Hydrochloride

Attention

Template: Infobox chemical / molecular formula search available

Sarpogrelate is a drug which is used as a platelet aggregation inhibitor for the treatment of strokes, heart attacks and other circulatory disorders. Furthermore, it could be demonstrated in clinical trials pectoris sarpogrelate for inhibiting the progression of atherosclerosis as well as effectiveness in the treatment of coronary heart disease and angina. Its effectiveness is based on inhibition of serotonin receptors of type 5 -HT2A and 5- HT2B on the platelets and blood vessels.

Synthesis

The synthesis of sarpogrelate is performed in several steps starting from 2-hydroxy -3'- methoxybibenzyl. In the first step, the intermediate 2 is prepared by reacting the starting material with epichlorohydrin in the presence of sodium hydride - (2,3 -epoxypropoxy ) -3'- methoxybibenzyl obtained. -3'- methoxybibenzyl this is implemented in connection with dimethylamine to form 2 - - [( dimethylamino )-2- hydroxypropoxy 3]. The free hydroxy group is esterified with succinic anhydride to the final product sarpogrelate.

Trade names

Sarpogrelate is marketed since 1993 in the Asian market by Mitsubishi -Tokyo Pharmaceuticals under the brand name Anplag.